Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Mallinckrodt
Moodys
Harvard Business School
McKesson

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for AZD-6280

See Plans and Pricing

« Back to Dashboard

What is the drug development status for AZD-6280?

AZD-6280 is an investigational drug.

There have been 30 clinical trials for AZD-6280. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2006.

The most common disease conditions in clinical trials are Adenocarcinoma, Ovarian Neoplasms, and Small Cell Lung Carcinoma. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Samsung Medical Center.

Recent Clinical Trials for AZD-6280
TitleSponsorPhase
Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerNational Cancer Institute (NCI)Phase 2
Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerM.D. Anderson Cancer CenterPhase 2
Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian CancerAstraZenecaPhase 2

See all AZD-6280 clinical trials

Clinical Trial Summary for AZD-6280

Top disease conditions for AZD-6280
Top clinical trial sponsors for AZD-6280

See all AZD-6280 clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
McKinsey
Mallinckrodt
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.